NCT01970540View on ClinicalTrials.gov

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 25, 2011

Primary Completion Date

August 9, 2017

Study Completion Date

August 9, 2017

Conditions
Endometrial AdenocarcinomasNeuroendocrine TumorsSmall-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Interventions
DRUG

lurbinectedin (PM01183)

lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.

DRUG

Doxorubicin

Commercially available presentations of vials containing doxorubicin will be provided as appropriate.

Trial Locations (7)

28033

Centro Oncológico Md Anderson International España, Madrid

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Universitario Fundación Jiménez, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

46009

Fundación Instituto Valenciano de Oncología, Valencia

08035

Hospital Universitari Vall D'Hebron, Barcelona

WC1E 6DB

UCLH (University College London Hospitals), London

Sponsors

Lead Sponsor

PharmaMar
All Listed Sponsors
lead

PharmaMar

INDUSTRY

NCT01970540 - Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter